InflaRx (IFRX) Other Non-Current Assets (2016 - 2026)
InflaRx's (IFRX) quarterly Other Non-Current Assets came in at $146691.2 in Q2 2026, down 27.08% year-over-year from $201167.3 in Q2 2025, and down 9.98% quarter-over-quarter from $162958.4 in Q1 2026.
Analysis
InflaRx (IFRX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has disclosed Other Non-Current Assets across 11 years of filings, most recently posting $146691.2 for Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 27.08% year-over-year to $146691.2; the TTM figure through Jun 2026 stood at $146691.2 (down 27.08% YoY), while the FY2025 annual figure was $170825.2, down 21.73% from the prior year.
- Other Non-Current Assets came in at $146691.2 for Q2 2026 at InflaRx, down from $162958.4 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $372098.7 in Q1 2022 to a low of $146691.2 in Q2 2026.
- Average Other Non-Current Assets over 5 years is $258566.6, with a median of $256786.9 recorded in 2024.
- Year-over-year, Other Non-Current Assets declined 11.71% in 2022 and fell 27.08% in 2026.
- Over 5 years, Other Non-Current Assets stood at $314303.5 in 2022, then slipped by 11.93% to $276803.8 in 2023, then decreased by 21.16% to $218242.4 in 2024, then retreated by 19.36% to $176001.1 in 2025, then slipped by 16.65% to $146691.2 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $146691.2 in Q2 2026, $162958.4 in Q1 2026, and $176001.1 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 146,691.23 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 146,691.23 |
| Mar 31, 2026 | 162,958.43 |
| Dec 31, 2025 | 176,001.05 |
| Sep 30, 2025 | 192,259.29 |
| Jun 30, 2025 | 201,167.35 |
| Mar 31, 2025 | 200,882.58 |
| Dec 31, 2024 | 218,242.44 |
| Sep 30, 2024 | 238,852.86 |
| Jun 30, 2024 | 248,491.81 |
| Mar 31, 2024 | 265,082.05 |
| Dec 31, 2023 | 276,803.83 |
| Sep 30, 2023 | 294,492.03 |
| Jun 30, 2023 | 309,019.32 |
| Mar 31, 2023 | 318,805.06 |
| Dec 31, 2022 | 314,303.52 |
| Sep 30, 2022 | 353,470.73 |
| Jun 30, 2022 | 364,576.99 |
| Mar 31, 2022 | 372,098.72 |
| Dec 31, 2021 | 385,021.73 |
| Sep 30, 2021 | 401,632.24 |